EZH2 and neoplasm: Immunohistochemical analyses of tumor tissue from a patient with chordoma samples treated with the EZH2 inhibitor tazemetostat demonstrated a decrease in H3K27me3 immunohistochemistry (IHC) staining and an increase of tumor-infiltrating lymphocytes (TILs) in on-treatment tumor biopsies in comparison to baseline.